Effect of Saxagliptin on Cognitive Function in Diabetes Patients After Stroke

Effect of Saxagliptin on Cognitive Function in Patients with Type 2 Diabetes After Ischemic Stroke

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000029688

Enrollment

Unknown

Registered

2020-02-09

Start date

2020-03-01

Completion date

Unknown

Last updated

2020-02-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes

Interventions

experimental group:Saxagliptin

control group:Glezit

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: With reference to the 1999 WHO Diabetes Diagnostic Criteria and the relevant criteria adopted at the 1995 National Fourth Cerebral Vascular Disease Conference, the diagnosis was acute cerebral infarction and diabetes, with the time from onset to hospitalization <= 24 h.

Exclusion criteria

Exclusion criteria: 1. Cannot take care of themselves before the illness; 2. Patients with trauma, infection, autoimmune disease, malignant tumor; 3. Serious insufficiency of heart, liver, kidney and other organs. 4. With history of diseases affecting cognitive function; 5. With significant visual, auditory, language, or physical impairments.

Design outcomes

Primary

Measure	Time frame
MOCA??;	—

Secondary

Measure	Time frame
Serum glucose;Biochemical parameters;	—

Countries

China

Contacts

Public ContactLi Sen

Liaocheng People's Hospital

lisendr@163.com+86 18701076712

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026